Institution
Integris Baptist Medical Center
Healthcare•Oklahoma City, Oklahoma, United States•
About: Integris Baptist Medical Center is a healthcare organization based out in Oklahoma City, Oklahoma, United States. It is known for research contribution in the topics: Transplantation & Extracorporeal membrane oxygenation. The organization has 340 authors who have published 361 publications receiving 13242 citations.
Topics: Transplantation, Extracorporeal membrane oxygenation, Ventricular assist device, Liver transplantation, Heart failure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A recombinant ApoA-I Milano/phospholipid complex administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS, and results require confirmation in larger clinical trials with morbidity and mortality end points.
Abstract: ContextAlthough low levels of high-density lipoprotein cholesterol (HDL-C)
increase risk for coronary disease, no data exist regarding potential benefits
of administration of HDL-C or an HDL mimetic. ApoA-I Milano is a variant of
apolipoprotein A-I identified in individuals in rural Italy who exhibit very
low levels of HDL. Infusion of recombinant ApoA-I Milano–phospholipid
complexes produces rapid regression of atherosclerosis in animal models.ObjectiveWe assessed the effect of intravenous recombinant ApoA-I Milano/phospholipid
complexes (ETC-216) on atheroma burden in patients with acute coronary syndromes
(ACS).DesignThe study was a double-blind, randomized, placebo-controlled multicenter
pilot trial comparing the effect of ETC-216 or placebo on coronary atheroma
burden measured by intravascular ultrasound (IVUS).SettingTen community and tertiary care hospitals in the United States.PatientsBetween November 2001 and March 2003, 123 patients aged 38 to 82 years
consented, 57 were randomly assigned, and 47 completed the protocol.InterventionsIn a ratio of 1:2:2, patients received 5 weekly infusions of placebo
or ETC-216 at 15 mg/kg or 45 mg/kg. Intravascular ultrasound was performed
within 2 weeks following ACS and repeated after 5 weekly treatments.Main Outcome MeasuresThe primary efficacy parameter was the change in percent atheroma volume
(follow-up minus baseline) in the combined ETC-216 cohort. Prespecified secondary
efficacy measures included the change in total atheroma volume and average
maximal atheroma thickness.ResultsThe mean (SD) percent atheroma volume decreased by −1.06% (3.17%)
in the combined ETC-216 group (median, −0.81%; 95% confidence interval
[CI], −1.53% to −0.34%; P = .02 compared
with baseline). In the placebo group, mean (SD) percent atheroma volume increased
by 0.14% (3.09%; median, 0.03%; 95% CI, −1.11% to 1.43%; P = .97 compared with baseline). The absolute reduction in atheroma
volume in the combined treatment groups was −14.1 mm3 or
a 4.2% decrease from baseline (P<.001).ConclusionsA recombinant ApoA-I Milano/phospholipid complex (ETC-216) administered
intravenously for 5 doses at weekly intervals produced significant regression
of coronary atherosclerosis as measured by IVUS. Although promising, these
results require confirmation in larger clinical trials with morbidity and
mortality end points.
1,745 citations
••
TL;DR: Treatment of patients with CDI should be stratified depending on whether they have mild-to-moderate, severe, or complicated disease, and a classification of disease severity is proposed to guide therapy that is useful for clinicians.
1,464 citations
••
TL;DR: FMT is a rational, durable, safe, and acceptable treatment option for patients with recurrent CDI and while no definite adverse effects of FMT were noted, two patients had improvement in a pre-existing medical condition and four patients developed diseases of potential interest after FMT.
624 citations
••
TL;DR: Among patients with advanced heart failure, implantation of a fully magnetically levitated centrifugal‐flow pump was associated with better outcomes at 6 months than was implanted of an axial‐ flow pump, primarily because of the lower rate of reoperation for pump malfunction.
Abstract: BackgroundContinuous-flow left ventricular assist systems increase the rate of survival among patients with advanced heart failure but are associated with the development of pump thrombosis. We investigated the effects of a new magnetically levitated centrifugal continuous-flow pump that was engineered to avert thrombosis. MethodsWe randomly assigned patients with advanced heart failure to receive either the new centrifugal continuous-flow pump or a commercially available axial continuous-flow pump. Patients could be enrolled irrespective of the intended goal of pump support (bridge to transplantation or destination therapy). The primary end point was a composite of survival free of disabling stroke (with disabling stroke indicated by a modified Rankin score >3; scores range from 0 to 6, with higher scores indicating more severe disability) or survival free of reoperation to replace or remove the device at 6 months after implantation. The trial was powered for noninferiority testing of the primary end poi...
574 citations
••
Brigham and Women's Hospital1, NewYork–Presbyterian Hospital2, University of Chicago3, Anschutz Medical Campus4, Columbia University5, Duke University6, Washington University in St. Louis7, Piedmont Hospital8, Advocate Lutheran General Hospital9, Integris Baptist Medical Center10, Carolinas Medical Center11
TL;DR: In patients with advanced heart failure, a fully magnetically levitated centrifugal‐flow pump was superior to a mechanical‐bearing axial‐ flow pump with regard to survival free of disabling stroke or reoperation to replace or remove a malfunctioning device.
Abstract: Background In an early analysis of this trial, use of a magnetically levitated centrifugal continuous-flow circulatory pump was found to improve clinical outcomes, as compared with a mechanical-bearing axial continuous-flow pump, at 6 months in patients with advanced heart failure. Methods In a randomized noninferiority and superiority trial, we compared the centrifugal-flow pump with the axial-flow pump in patients with advanced heart failure, irrespective of the intended goal of support (bridge to transplantation or destination therapy). The composite primary end point was survival at 2 years free of disabling stroke (with disabling stroke indicated by a modified Rankin score of >3; scores range from 0 to 6, with higher scores indicating more severe disability) or survival free of reoperation to replace or remove a malfunctioning device. The noninferiority margin for the risk difference (centrifugal-flow pump group minus axial-flow pump group) was −10 percentage points. Results Of 366 patients,...
565 citations
Authors
Showing all 340 results
Name | H-index | Papers | Citations |
---|---|---|---|
David R. Nelson | 94 | 417 | 35479 |
David K. C. Cooper | 87 | 932 | 30518 |
William E. Whitehead | 87 | 442 | 31173 |
David H. Van Thiel | 75 | 417 | 20427 |
Tarek Hassanein | 58 | 235 | 14767 |
Michael D. Crowell | 57 | 289 | 13069 |
D. H. Van Thiel | 57 | 311 | 12105 |
John M. Rose | 55 | 300 | 15048 |
Lawrence J. Cheskin | 49 | 229 | 10013 |
Stefano Fagiuoli | 46 | 308 | 8386 |
Brian L. Erstad | 40 | 239 | 5641 |
James W. Long | 35 | 141 | 7831 |
Aly El-Banayosy | 34 | 142 | 4652 |
Steven G. Chrysant | 32 | 171 | 4281 |
Ghazi M. Rayan | 29 | 128 | 2862 |